EPISODE · Apr 30, 2024 · 14 MIN
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.
from Answers from the Lab · host Mayo Clinic Laboratories
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the condition, which severely impacts multiple organs and blood.(00:31) Could you please provide a little bit about yourself and your background? (01:30) Would you please share a brief overview of the UBA1Q assay? (02:13) Would you provide an overview of VEXAS syndrome? (05:30) When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome? (06:38) What advantage does this assay provide over other methodologies? (10:13) Could you share further why diagnosis is so important for these patients?(12:40) Is there anything else you'd like to comment about the assay?
What this episode covers
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the condition, which severely impacts multiple organs and blood.(00:31) Could you please provide a little bit about yourself and your background? (01:30) Would you please share a brief overview of the UBA1Q assay? (02:13) Would you provide an overview of VEXAS syndrome? (05:30) When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome? (06:38) What advantage does this assay provide over other methodologies? (10:13) Could you share further why diagnosis is so important for these patients?(12:40) Is there anything else you'd like to comment about the assay?
NOW PLAYING
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m